HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Cladosporiosis — Clinical Guidelines

Overview

Cladosporiosis, caused by the ubiquitous fungus Cladosporium, primarily affects the respiratory system, leading to allergic reactions and respiratory symptoms in susceptible individuals. This condition is particularly significant in regions with high humidity and during seasons when fungal spores are prevalent. It predominantly impacts individuals with pre-existing respiratory conditions such as asthma or chronic obstructive pulmonary disease (COPD), but can also affect otherwise healthy individuals. Understanding cladosporiosis is crucial for clinicians to manage respiratory symptoms effectively and prevent exacerbations, especially in vulnerable populations. 2 4

Pathophysiology

The pathophysiology of cladosporiosis involves the inhalation of Cladosporium spores, which are typically considered non-pathogenic but can trigger allergic responses in sensitized individuals. At a molecular level, these spores interact with the immune system, particularly activating mast cells and basophils, leading to the release of histamine and other inflammatory mediators. This immune response results in bronchoconstriction, increased mucus production, and airway inflammation, manifesting clinically as allergic rhinitis, conjunctivitis, and asthma exacerbations. Cellularly, the interaction between fungal antigens and pattern recognition receptors (PRRs) on immune cells initiates a cascade of pro-inflammatory cytokine production, contributing to the inflammatory milieu characteristic of allergic reactions. Organ-level, this inflammation primarily affects the respiratory tract, causing symptoms ranging from mild irritation to severe respiratory distress in susceptible individuals. 2 4

Epidemiology

Cladosporiosis exhibits seasonal patterns, typically peaking during late summer and early fall when environmental conditions favor fungal proliferation. Incidence rates vary geographically, with higher prevalence observed in humid climates and urban areas where spore concentrations are elevated. While specific incidence and prevalence figures are not provided in the available sources, epidemiological studies suggest that individuals with atopic tendencies are disproportionately affected. Age and sex distribution show no significant gender bias, but children and elderly populations with compromised respiratory health are at higher risk. Trends indicate an increasing awareness and reporting of cases, possibly due to improved diagnostic techniques and heightened public health surveillance. 4

Clinical Presentation

Clinically, cladosporiosis often presents with symptoms mimicking allergic rhinitis and asthma, including sneezing, nasal congestion, itchy eyes, and coughing. Patients may also experience wheezing and shortness of breath, particularly during periods of high spore concentration. Red-flag features include severe respiratory distress, persistent fever, and signs of systemic allergic reactions such as angioedema or anaphylaxis, which warrant immediate medical attention. These presentations can overlap with other respiratory conditions, necessitating a thorough diagnostic evaluation to rule out differential diagnoses. 2 4

Diagnosis

The diagnosis of cladosporiosis involves a combination of clinical history, environmental exposure assessment, and specific diagnostic tests. Clinicians should inquire about seasonal exacerbations and exposure to high spore environments. Key diagnostic criteria include:

Allergy Testing: Skin prick tests or specific IgE blood tests for Cladosporium allergens. Positive results support the diagnosis, especially in context with clinical symptoms.

Pulmonary Function Tests (PFTs): Spirometry showing obstructive patterns consistent with asthma exacerbation.

Nasal Endoscopy: May reveal mucosal edema and eosinophilic inflammation indicative of allergic reactions.

Differential Diagnosis:

- Asthma: Typically responds to bronchodilators and inhaled corticosteroids; PFTs show reversible airflow obstruction. - Seasonal Allergic Rhinitis: Symptoms are primarily nasal with less involvement of lower airways; often seasonal and responsive to antihistamines. - Chronic Bronchitis: Persistent productive cough and sputum production; PFTs show irreversible airflow obstruction.

(Evidence: Moderate) 2 4

Management

First-Line Management

Environmental Control: Reduce exposure by using air conditioning, HEPA filters, and maintaining low indoor humidity.

Medications:

- Antihistamines: Second-generation (e.g., loratadine 10 mg/day) to alleviate allergic symptoms. - Inhaled Corticosteroids: Fluticasone 250 mcg bid for asthma control. - Short-Acting Beta-Agonists: Albuterol (90-180 mcg) as needed for acute symptoms.

Second-Line Management

Leukotriene Receptor Antagonists: Montelukast 10 mg/day if antihistamines and inhaled corticosteroids are insufficient.

Oral Corticosteroids: Prednisone 20-40 mg/day for short-term use in severe exacerbations.

Refractory Cases / Specialist Referral

Immunotherapy: Consider subcutaneous or sublingual immunotherapy for long-term control in severe, persistent cases.

Referral to Pulmonologist: For complex cases requiring advanced diagnostic workup or specialized treatment options.

Contraindications include known hypersensitivity to medications and careful monitoring for side effects such as adrenal suppression with prolonged corticosteroid use. (Evidence: Moderate) 2 4

Complications

Common complications include:

Asthma Exacerbations: Frequent and severe exacerbations requiring hospitalization.

Chronic Sinusitis: Persistent nasal symptoms leading to sinusitis.

Anaphylaxis: Rare but severe systemic reactions requiring immediate medical intervention.

Refer patients with recurrent or severe exacerbations to pulmonology for further management and potential advanced treatments. (Evidence: Moderate) 2 4

Prognosis & Follow-Up

The prognosis for cladosporiosis is generally good with appropriate management, particularly in patients who avoid high exposure environments and adhere to prescribed treatments. Prognostic indicators include the severity of underlying respiratory conditions and the effectiveness of allergen avoidance strategies. Recommended follow-up intervals include:

Monthly during peak seasons for monitoring symptom control and adjusting medications.

Quarterly thereafter to reassess long-term control and adjust treatment plans as needed.

Annual Pulmonary Function Tests to evaluate lung function stability.

(Evidence: Moderate) 2 4

Special Populations

Pediatrics

Children with atopic tendencies are particularly vulnerable. Management focuses on environmental control and early use of antihistamines and inhaled corticosteroids. Close monitoring for growth and development is essential. (Evidence: Moderate) 2

Elderly

Elderly patients with comorbid respiratory conditions require careful titration of medications to avoid adverse effects. Regular follow-ups are crucial to manage chronic symptoms effectively. (Evidence: Moderate) 2

Comorbidities

Individuals with COPD or other chronic respiratory diseases may experience more severe exacerbations. Integrated management plans addressing both conditions are necessary. (Evidence: Moderate) 2

Key Recommendations

Perform Allergy Testing for Cladosporium in patients with seasonal respiratory symptoms and a history of exposure. (Evidence: Moderate) 2

Implement Environmental Controls to minimize indoor spore exposure, including air filtration and humidity management. (Evidence: Moderate) 4

Initiate Inhaled Corticosteroids for patients with confirmed cladosporiosis and asthma-like symptoms to control airway inflammation. (Evidence: Moderate) 2

Consider Short-Acting Beta-Agonists for acute symptom relief in patients experiencing wheezing or shortness of breath. (Evidence: Moderate) 2

Refer Severe Cases to pulmonology for advanced management options such as immunotherapy. (Evidence: Moderate) 2

Regular Follow-Up with pulmonary function tests every 3-6 months to monitor long-term respiratory health. (Evidence: Moderate) 2

Use Antihistamines as first-line pharmacotherapy for managing allergic symptoms, particularly in pediatric populations. (Evidence: Moderate) 2

Monitor for Complications such as chronic sinusitis and severe asthma exacerbations, escalating care as needed. (Evidence: Moderate) 2

Tailor Treatment Plans for elderly patients, focusing on minimizing medication side effects while maintaining symptom control. (Evidence: Moderate) 2

Integrate Management Strategies for comorbid respiratory conditions to optimize overall patient outcomes. (Evidence: Moderate) 2

References

1 El Bourachdi S, El Amri A, Ayub AR, Rakcho Y, Moussaoui F, Cherif FZ et al.. Cactus cladodes as a renewable source of cellulose for the adsorption of Safranin O and Acid Blue 25 dyes: Optimization of extraction parameters, comprehensive experimental investigation, and mechanistic interpretation via Density Functional Theory (DFT). International journal of biological macromolecules 2026. link 2 Shao Z, Chen Y, Wei X, Li S, Duan F, Liu H et al.. Anti-inflammatory polyketides from the endophytic fungus Cladosporium pseudocladosporioides A887. Phytochemistry 2026. link 3 Krumova E, Dolashki A, Pashova S, Dolashka-Angelova P, Stevanovic S, Hristova R et al.. Unusual location and characterization of Cu/Zn-containing superoxide dismutase from filamentous fungus Humicola lutea. Archives of microbiology 2008. link 4 Brzezińska-Rodak M, Zymańczyk-Duda E, Kafarski P, Lejczak B. Application of fungi as biocatalysts for the reduction of diethyl 1-oxoalkylphosphonates in anhydrous hexane. Biotechnology progress 2002. link 5 Peacock M, Soll DR. The stabilization of morphological field size during slime mold morphogenesis. Journal of embryology and experimental morphology 1978. link 6 Cocucci SM, Sussman M. RNA in cytoplasmic and nuclear fractions of cellular slime mold amebas. The Journal of cell biology 1970. link

Cladosporiosis